Articles for 2011
Our articles for 2011 are shown below.
-
Cambridge Enterprise announces 2011 results
Income generated from the University of Cambridge’s commercialisation activities continued to rise in 2011, as did the number of intellectual property, consultancy and equity agreements signed on behalf of the University and its researchers.
-
Research reveals shocking new way to create nanoporous materials
Research demonstrates simple, scaleable method with realistic capability of industrial cross-over.
-
Horizon Discovery announces collaboration with the National Cancer Institute and the National Human Genome Research Institute
Horizon’s rAAV gene targeting to be applied in cancer research programmes, enabling the NCI and NHGRI to engineer human isogenic disease models.
-
New treatment for multiple sclerosis: Cambridge University translates research at the bench into a drug at the bedside
Phase III clinical trials for new MS drug very positive.
-
Free course on performing expert witness work
Cambridge Enterprise is offering a free course on the advantages and potential issues associated with serving as an expert witness in a court case, on Wednesday, 14 December.
-
Using sub-nanometre cages to identify molecules
Reliable and accurate single-molecule medical diagnosis is a step closer to reality with the development a new technique by Cambridge University researchers which uses sub-nanometre ‘cages’ to capture and identify molecules.
-
New Chief Executive at Cambridge Enterprise
The University of Cambridge has announced the appointment of Dr Tony Raven as the new Chief Executive of Cambridge Enterprise, effective 1 December.
-
Two Cambridge companies in the Guardian Cleantech 100
Two companies based on University of Cambridge research have been included on the Guardian’s Cleantech 100 list, designed to recognise the most exciting, innovative and up-and-coming clean technology companies in the world.
-
Biomarker signature identified for Crohn's and ulcerative colitis
Researchers at the University of Cambridge have identified a biomarker signature which could predict disease progression in patients with Crohn’s and ulcerative colitis, allowing clinicians to target treatment more effectively.
-
Researchers develop new test for children with vision loss
Technology developed at the University of Cambridge to detect peripheral visual field loss in young children will enable the earlier detection of brain tumours, potentially saving sight and lives.